Monterey Bio Acquisition Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTRY research report →
Price Chart
About the company
Monterey Bio Acquisition Corporation currently lacks substantial operational activities. Its primary goal is to achieve a business combination—including but not limited to mergers, capital stock exchanges, asset acquisitions, or reorganizations—with companies in the biotechnology industry. The firm, established in 2020, was formerly known as Chardan FinTech Acquisition Corp.
- CEO
- Murat Omur
- IPO
- 2021
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on MTRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $48.30M
- P/E
- -25.32
- PEG
- 0.44
- P/S
- 0.00
- P/B
- 1.62
- EV/EBITDA
- -23.62
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1.86%
- ROIC
- -10.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,039,000+0.0%
- Op Income
- $-2,039,000
- Net Income
- $-1,274,000-119.3%
- EPS
- $-0.44-989.1%
- OCF Growth
- -6.8%
- FCF Growth
- -6.8%
- 52W High
- $12.00
- 52W Low
- $10.21
- 50D MA
- $11.21
- 200D MA
- $11.03
- Beta
- 0.00
- RSI (14)
- 41
- Avg Volume
- 3.45K
No earnings-call transcripts are available for MTRY yet.
- Free Float
- 25.3%
- Shares Outstanding
- 4.34M
- Float Shares
- 1.10M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.43. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 9, 23 | Chardan Monterey Investments LLC | buy | 478,125 |
| Mar 9, 23 | Chardan Monterey Investments LLC | sell | 13,125 |
| Sep 29, 22 | Chardan Monterey Investments LLC | other | 0 |
| Mar 9, 23 | GROSSMAN JONAS | buy | 478,125 |
| Mar 9, 23 | GROSSMAN JONAS | sell | 13,125 |
| Mar 9, 23 | NORTHSTAR BIO VENTURES, LLC | other | 75,000 |
| Mar 9, 23 | NORTHSTAR BIO VENTURES, LLC | sell | 570,000 |
| Mar 9, 23 | McKeever William | other | 0 |
| Mar 9, 23 | Satyal Sanjeev | other | 75,000 |
| Mar 9, 23 | Patel Sandip I | other | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MTRY coverage
Recent articles, reports, and earnings notes.
No research on MTRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTRY report →